SEATTLE--(BUSINESS WIRE)--Bonum Therapeutics, a biotechnology company that is using its proprietary platform for conditional regulation to create highly active and less toxic medicines, today announced that it will present data on a new class of protein therapeutics with the potential for increased safety and efficacy in a wide range of biologic targets and disease areas.

西雅图--（商业新闻短讯）--生物技术公司Bonum Therapeutics今天宣布，它将提供一类新的蛋白质治疗剂的数据，这些蛋白质治疗剂有可能在广泛的生物靶标和疾病领域提高安全性和有效性，Bonum Therapeutics是一家利用其专有平台进行有条件监管以创造高活性和毒性较低的药物的生物技术公司。

Scientists from Bonum will present two posters at the upcoming Keystone Symposium, “Antibodies as Drugs: The Art in Antibody Engineering,” which will be held May 5-8 at the Beaver Run Conference Center in Breckenridge, CO..

博纳姆的科学家将在即将举行的Keystone研讨会上展示两幅海报，“抗体作为药物：抗体工程的艺术”，该研讨会将于5月5日至8日在布雷肯里奇的海狸营会议中心举行。。

“We are excited about the success of our platform technology with multiple conditionally active target/effector combinations, and we are particularly encouraged by the rapid progress of our lead program, cLAG3-IL2,” said John Mulligan, PhD, Bonum’s CEO and founder. “These presentations detail the strengths of Bonum’s platform technology and its application to the company’s lead asset.”.

Bonum首席执行官兼创始人约翰·穆利根（JohnMulligan）博士表示：“我们对平台技术的成功感到兴奋，平台技术采用了多种有条件的主动目标/效应器组合，我们的领先项目cLAG3-IL2取得了快速进展，这尤其让我们感到鼓舞。”。“这些演示详细介绍了Bonum平台技术的优势及其在公司领先资产中的应用。”。

Details of the poster presentations are as follows:

海报展示详情如下：

Title: “Development of a new class of targeted and conditional cytokine therapeutics using a novel dual-binding antibody-based platform.”

标题：“使用新型基于双结合抗体的平台开发一类新的靶向和条件性细胞因子治疗剂。”

Abstract: This poster will highlight Bonum’s unique dual-binding antibody platform technology which allows the generation of therapeutics with targeted, conditional cytokine activity only when bound to a selected marker. While the company’s current focus is on the development of therapeutics incorporating immunostimulatory cytokines, its technology can be applied to the regulation of any functional protein moieties, including agonist and antagonistic antibody binding domains, growth factors, and receptors..

摘要：这张海报将重点介绍Bonum独特的双结合抗体平台技术，该技术仅在与选定标记结合时才能产生具有靶向，条件性细胞因子活性的治疗剂。虽然该公司目前的重点是开发掺入免疫刺激细胞因子的治疗剂，但其技术可用于调节任何功能性蛋白质部分，包括激动剂和拮抗性抗体结合域，生长因子和受体。。

Title: “A novel method for generating regulated cytokine therapeutics: Safety and activity of a conditionally active cLAG3-IL2 in a simple antibody format.”

标题：“产生调节性细胞因子治疗剂的新方法：以简单抗体形式产生条件性活性cLAG3-IL2的安全性和活性。”

Abstract: This poster will highlight a conditionally active therapeutic called cLAG3-IL2, which targets IL-2 to LAG-3+ cells while remaining systemically inert, even at high treatment doses. The in vivo safety and efficacy data described in this poster demonstrate that this program is suitable for clinical development..

摘要：这张海报将重点介绍一种称为cLAG3-IL2的条件性活性治疗剂，它将IL-2靶向LAG-3+细胞，同时即使在高治疗剂量下也保持全身惰性。本海报中描述的体内安全性和有效性数据表明，该计划适用于临床开发。。

The conference organizers have selected Bonum’s poster on its cLAG3-IL2 program for presentation as a short talk during the session “Orchestrating Immune Defense Against Cancer by Antibody Engineering” on May 7 from 8 a.m. to 11 a.m. Dr. Mulligan will give the talk, titled “A novel method for generating regulated cytokine therapeutics: Safety and activity of a conditionally active cLAG3-IL2 in a simple antibody format.”.

会议组织者选择了Bonum在其cLAG3-IL2项目上的海报，作为5月7日上午8点至11点“通过抗体工程协调免疫防御癌症”会议期间的简短演讲。Mulligan博士将发表题为“产生受调节细胞因子治疗剂的新方法：以简单抗体形式有条件活性的cLAG3-IL2的安全性和活性”的演讲。

The posters will be available on the Bonum website on Monday, May 6, at noon Mountain Time.

海报将于5月6日星期一中午山区时间在Bonum网站上发布。

Bonum is developing new therapies based on its proprietary platform of conditionally active therapeutics. The company is a spinout of Good Therapeutics, which developed the technology that Bonum is advancing. The merits of the platform were validated by the Roche acquisition of Good Therapeutics for its PD-1-regulated IL-2 program in September 2022..

Bonum正在开发基于其专有的条件活性治疗平台的新疗法。该公司是Good Therapeutics的衍生产品，开发了Bonum正在推进的技术。2022年9月，罗氏为其PD-1调节的IL-2计划收购了良好的治疗药物，从而验证了该平台的优点。。

About Bonum Therapeutics

关于Bonum Therapeutics

Bonum Therapeutics is a privately held biotechnology company focused on the generation of a new class of therapeutics based on a proven technology platform that utilizes principles of regulation to create highly active and less toxic medicines. The company was founded in 2022 as a spinout of Good Therapeutics, following the sale of Good to Roche in September 2022 for $250 million, plus significant milestones.

Bonum Therapeutics是一家私营生物技术公司，专注于基于成熟的技术平台开发一类新的治疗药物，该平台利用监管原则来生产高活性和低毒的药物。该公司成立于2022年，是Good Therapeutics的衍生产品，继2022年9月以2.5亿美元的价格将Good出售给罗氏之后，再加上重要的里程碑。

Using a novel approach, Bonum’s molecules combine a sensor component directed against a specific biological marker and a therapeutic component. When the sensor binds its target, the molecule reversibly changes shape and becomes active, delivering potent activity only where it is needed. The technology is applicable to a wide range of therapeutic areas, including oncology, autoimmunity, metabolic disorders, and pain management.

使用一种新方法，Bonum的分子将针对特定生物标记的传感器组件和治疗组件结合起来。当传感器结合其靶标时，分子可逆地改变形状并变得活跃，仅在需要的地方提供有效的活性。该技术适用于广泛的治疗领域，包括肿瘤学，自身免疫，代谢紊乱和疼痛管理。

Bonum’s initial efforts are focusing on regulated immunocytokines, including conditionally active IFN-alpha, IL-12, and TGF-beta, while it pursues additional applications in partnership with others..

Bonum最初的努力集中在受调节的免疫细胞因子上，包括有条件活性的IFN-α，IL-12和TGF-β，同时与其他人合作寻求其他应用。。

The company is backed by a group of leading venture investors including Rivervest Venture Partners, Roche Venture Fund, Digitalis Ventures, American Century Investments, Codon Capital, and Vivo Capital. For more information, please visit our website at www.BonumTx.com and connect with us on LinkedIn and X (Twitter)..

该公司由一批领先的风险投资者支持，包括Rivervest venture Partners、Roche venture Fund、Digitalis Ventures、American Century Investments、Codon Capital和Vivo Capital。有关更多信息，请访问我们的网站www.BonumTx.com，并通过LinkedIn和X（Twitter）与我们联系。。